Erdosteine Market Size is valued at USD 147.21 Mn in 2022 and is predicted to reach USD 301.61 Mn by the year 2031 at a 8.45% CAGR during the forecast period for 2023-2031.
The changing environment, including increased air pollution and cigarette or tobacco smoking, has resulted in an increase in respiratory disorders and ailments. Prolonged exposure to chemicals in industrial units, as well as indoor pollution in rural areas, leads to the increased prevalence of lung diseases/disorders. The airflow obstruction can cause chronic coughing, wheezing, nausea, and vomiting. It can also reduce the quality of life for those who are suffering. Growing emphasis on illness prevention rather than treatment, as well as government prioritization of healthcare resources, has resulted in increased use of erdosteine by research institutes.
The rising prevalence of chronic diseases in adults, such as obesity, diabetes, and heart disease, has boosted the demand for therapeutic treatments, which should propel the pharmaceutical research industry and boost the erdosteine market share.
The Erdosteine Market is segmented on the basis of end-user and application. End-user segment includes pharmaceutical, research institutes, contract manufacturing organizations, and others. By application, the market is segmented into bronchitis, chronic obstructive pulmonary disease, nasopharyngitis, and others.
The pharmaceutical category is expected to hold a major share of the global Erdosteine Market in 2022. The rising pharmaceutical sectors of India and China have considerably contributed to the segment's market expansion. Collaborations, mergers, acquisitions, partnerships, and agreements between market players to develop novel pharmaceuticals and product innovation in the pharmaceutical sector will help boost the segment's growth. Furthermore, the massive and extensive distribution and retail network of drug stores aids pharmaceutical growth by broadening their reach and boosting medicine accessibility. Increased R&D will also fuel the segment's growth. Furthermore, fiscal investment is expected to expand, assisting the pharmaceutical sector in growth during the projection period.
The chronic obstructive pulmonary disease segment is projected to grow at a rapid rate in the global Erdosteine Market. COPD is a long-term inflammatory lung disorder that reduces airflow. Wheezing, coughing up mucus (sputum), and difficulty breathing are among the symptoms. The ageing population will boost the prevalence of COPD. Furthermore, rising e-cigarette and tobacco consumption will contribute to the global rise in COPD prevalence. COPD is prevalent, causing 3 to 4 million deaths worldwide each year. It is life-threatening if not treated and can progress to other catastrophic health concerns. As a result, the rising incidence and majority of chronic obstructive pulmonary disease will drive the segment's expansion.
The North America Erdosteine Market is expected to report the highest market share in terms of revenue shortly. The region's young individuals are particularly vulnerable to smoking and tobacco consumption. The increasing popularity of e-cigarettes adds to the region's already pervasive substance misuse problem. Given the problematic job life or life, the stressful contemporary lifestyle has also boosted tobacco intake and cigarette smoking. Furthermore, occupational exposure to harmful particulates and rising air pollution in the Asia Pacific lead to chronic lung conditions/diseases. The pharmaceutical industry's vast and ever-expanding drug supply matches the need for erdosteine. Large pharmaceutical businesses in the region stimulate research and development of novel pharmaceuticals, ultimately boosting the region's growth. Rising government healthcare spending will help the growth of the regional erdosteine market in the coming years.
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 147.21 Mn |
|
Revenue Forecast In 2031 |
USD 301.61 Mn |
|
Growth Rate CAGR |
CAGR of 8.45% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn, and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By End-user and Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Alitair Pharmaceuticals, Berchemia Healthcare, Delta Finochem Pvt. Ltd., Edmond Pharmaceuticals, Hanmi Pharmaceuticals Co. Ltd., Hikma Pharmaceuticals, Recipharm AB, Shandong Luoxin Pharmaceuticals, Shanghai Pukang Pharmaceutical, Zhejiang Pharmaceutical Co. Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Erdosteine Market Snapshot
Chapter 4. Global Erdosteine Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By End-User Estimates & Trend Analysis
5.1. By End-User, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By End-User:
5.2.1. Pharmaceuticals
5.2.2. Research Institutes
5.2.3. Contract Manufacturing Organizations
5.2.4. Others
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. By Application & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Application:
6.2.1. Bronchitis
6.2.2. Chronic Obstructive Pulmonary Disease
6.2.3. Nasopharyngitis
6.2.4. Others
Chapter 7. Erdosteine Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Erdosteine Market revenue (US$ Million) estimates and forecasts By End-User, 2019-2031
7.1.2. North America Erdosteine Market revenue (US$ Million) estimates and forecasts By Application, 2019-2031
7.1.3. North America Erdosteine Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
7.2. Europe
7.2.1. Europe Erdosteine Market revenue (US$ Million) By End-User, 2019-2031
7.2.2. Europe Erdosteine Market revenue (US$ Million) By Application, 2019-2031
7.2.3. Europe Erdosteine Market revenue (US$ Million) by country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Erdosteine Market revenue (US$ Million) By End-User, 2019-2031
7.3.2. Asia Pacific Erdosteine Market revenue (US$ Million) By Application, 2019-2031
7.3.3. Asia Pacific Erdosteine Market revenue (US$ Million) by country, 2019-2031
7.4. Latin America
7.4.1. Latin America Erdosteine Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031
7.4.2. Latin America Erdosteine Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
7.4.3. Latin America Erdosteine Market revenue (US$ Million) by country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Erdosteine Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031
7.5.2. Middle East & Africa Erdosteine Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
7.5.3. Middle East & Africa Erdosteine Market revenue (US$ Million) by country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Alitair Pharmaceuticals
8.2.2. Berchemia Healthcare
8.2.3. Delta Finochem Pvt. Ltd.
8.2.4. Edmond Pharmaceuticals
8.2.5. Hanmi Pharmaceuticals Co. Ltd.
8.2.6. Hikma Pharmaceuticals
8.2.7. Recipharm AB
8.2.8. Shandong Luoxin Pharmaceuticals
8.2.9. Shanghai Pukang Pharmaceutical
8.2.10. Zhejiang Pharmaceutical Co. Ltd.
By End-User-
By Application-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
